Subcutaneous Immunotherapy for Allergic Rhinoconjunctivitis, Allergic Asthma, and Prevention of Allergic Diseases

2014 ◽  
pp. 349-359 ◽  
Author(s):  
Hans-Jørgen Malling ◽  
Jean Bousquet
Keyword(s):  
Allergic Asthma ◽  
Allergic Diseases ◽  
Allergic Rhinoconjunctivitis ◽  
Subcutaneous Immunotherapy

scholarly journals Is suicidal ideation associated with allergic asthma and allergic rhinitis?

2018 ◽  
Vol 44 (1) ◽  
pp. 31-35 ◽  
Author(s):  
Martín Bedolla-Barajas ◽  
Norma Angélica Pulido-Guillén ◽  
Bolívar Vivar-Aburto ◽  
Jaime Morales-Romero ◽  
José Raúl Ortiz-Peregrina ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Suicidal Ideation ◽  
Allergic Asthma ◽  
Allergic Diseases ◽  
Cross Sectional Study ◽  
University Hospital ◽  
Control Group ◽  
Healthy Controls ◽  
Cross Sectional ◽  
And Control

ABSTRACT Objective: To investigate whether there is an association between suicidal ideation (SI) and allergic diseases in adults. Methods: This was a comparative cross-sectional study involving individuals ranging from 20 to 50 years of age recruited from a university hospital in the city of Guadalajara, Mexico. We included patients with a confirmed diagnosis of allergic asthma, those with a confirmed diagnosis of allergic rhinitis, and healthy controls. All subjects completed the Beck Depression Inventory-II (BDI-II), which includes an item that evaluates the presence of suicidal thoughts or desires within the last two weeks, in order to identify SI. Results: The sample comprised 115 patients with allergic asthma, 111 patients with allergic rhinitis, and 96 healthy controls. The number of individuals identified with SI in the three groups were, respectively, 17 (14.8%), 13 (11.7%), and 8 (8.3%). Regarding the presence of SI, no statistically significant association was found in the allergic asthma group (OR = 1.98; 95% CI: 0.78-4.64; p = 0.154) or in the allergic rhinitis group (OR = 1.46; 95% CI: 0.58-3.68; p = 0.424) when they were compared with the control group. However, the presence of depression was associated with SI in the three groups: allergic asthma (OR = 12.36; 95% CI: 2.67-57.15; p = 0.001); allergic rhinitis (OR = 6.20; 95% CI: 1.66-23.14; p = 0.006); and control (OR = 21.0; 95% CI: 3.75-117.36; p < 0,001). Conclusions: In comparison with the control group, no association was found between SI and the groups with allergic diseases. In contrast, there was association between SI and depression in the three groups.

scholarly journals Allergen-specific subcutaneous immunotherapy in allergic asthma: immunologic mechanisms and improvement

2010 ◽  
Vol 5 (1) ◽  
pp. 5303 ◽  
Author(s):  
YousefA. Taher ◽  
PaulA.J. Henricks ◽  
AntoonJ.M. van Oosterhout
Keyword(s):  
Allergic Asthma ◽  
Subcutaneous Immunotherapy

scholarly journals IgE-Related Chronic Diseases and Anti-IgE-Based Treatments

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Arnau Navinés-Ferrer ◽  
Eva Serrano-Candelas ◽  
Gustavo-J Molina-Molina ◽  
Margarita Martín
Keyword(s):  
Allergic Asthma ◽  
Chronic Diseases ◽  
Chronic Urticaria ◽  
Inhaled Corticosteroids ◽  
Systemic Mastocytosis ◽  
Airway Remodeling ◽  
Clinical Manifestations ◽  
Allergic Diseases ◽  
Severe Allergic Asthma ◽  
Prophylactic Use

IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies with a probable allergic basis. This review focuses on IgE-related chronic diseases, such as allergic asthma and chronic urticaria (CU), and on the role of the anti-IgE monoclonal antibody, omalizumab, in their treatment. We also assess the off-label use of omalizumab for other pathologies associated with IgE and report the latest findings concerning this drug and other new related drugs. To date, omalizumab has only been approved for severe allergic asthma and unresponsive chronic urticaria treatments. In allergic asthma, omalizumab has demonstrated its efficacy in reducing the dose of inhaled corticosteroids required by patients, decreasing the number of asthma exacerbations, and limiting the effect on airway remodeling. In CU, omalizumab treatment rapidly improves symptoms and in some cases achieves complete disease remission. In systemic mastocytosis, omalizumab also improves symptoms and its prophylactic use to prevent anaphylactic reactions has also been discussed. In other pathologies such as atopic dermatitis, food allergy, allergic rhinitis, nasal polyposis, and keratoconjunctivitis, omalizumab significantly improves clinical manifestations. Omalizumab acts in two ways: by sequestering free IgE and by accelerating the dissociation of the IgE-Fcεreceptor I complex.

Side effects during subcutaneous immunotherapy in children with allergic diseases

2018 ◽  
Vol 29 (3) ◽  
pp. 267-274 ◽  
Author(s):  
Max A. Tophof ◽  
Anne Hermanns ◽  
Thomas Adelt ◽  
Peter Eberle ◽  
Christine Gronke ◽  
...  
Keyword(s):  
Side Effects ◽  
Allergic Diseases ◽  
Subcutaneous Immunotherapy
Sign in / Sign up

Export Citation Format

Share Document